Genetic Variability and Adiponectin in Metabolic Disorders

Adiponectin is an adipocyte-derived hormone that plays a central role in regulating glucose and lipid homeostasis. Circulating levels of this protein are modulated by genetic variation within the ADIPOQ locus and related regulatory regions, giving rise to interindividual differences in insulin sensitivity, inflammation and vascular health. Common and rare single-nucleotide polymorphisms (SNPs) can influence promoter activity, transcript stability and multimer formation, thereby altering bioactive concentrations in serum. Genetic variability in adiponectin not only impacts risk of type 2 diabetes and obesity but also contributes to the clustering of traits that define the metabolic syndrome, including dyslipidaemia, hypertension and nonalcoholic fatty liver disease. Beyond ADIPOQ, genome-wide studies have identified novel loci that affect adiponectin expression and downstream signalling, implicating pathways related to lipid metabolism, energy balance and tissue cross-talk. Interactions between genetic predisposition and environmental factors, such as diet, toxins and inflammatory stimuli, further shape the phenotypic spectrum of metabolic disorders. Understanding these complex relationships has global significance for disease stratification, preventive strategies and the development of targeted therapies that aim to restore adiponectin function or mimic its beneficial actions. Advances in genomic technologies and high-throughput assays now enable comprehensive characterisation of haplotypes, linkage disequilibrium patterns and epistatic effects, thereby refining the molecular map of adiponectin-related metabolic risk.

Research from Nature Portfolio

Recent studies have consolidated the association between ADIPOQ polymorphisms and hypertension, underscoring the vascular dimension of adiponectin genetics. A systematic meta-analysis of multiple cohorts demonstrated that alleles at key SNPs such as rs2241766 and rs266729 confer a significant increase in blood pressure risk under both recessive and dominant models. These findings confirm that genetic variation in adiponectin modulates endothelial function and arterial stiffness, linking adipokine dysregulation to the pathogenesis of cardiovascular and metabolic comorbidities.

Genetic Variability and Adiponectin in Metabolic Disorders publication trend

The graph below shows the total number of articles in genetic variability and adiponectin in metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Adiponectin: An adipose-derived hormone that enhances insulin sensitivity and exerts anti-inflammatory effects.

Single-nucleotide polymorphism: A variation at a single base in the genome that contributes to genetic diversity and disease risk.

Metabolic syndrome: A constellation of conditions—insulin resistance, dyslipidaemia, hypertension and central obesity—that increase cardiovascular risk.

Insulin resistance: A state in which cells exhibit reduced responsiveness to insulin, leading to impaired glucose uptake.

Genome-wide association study: A method that scans genetic variants across the genome to identify associations with traits or diseases.

References

1. The Polymorphism rs17300539 in the Adiponectin Promoter Gene Is Related to Metabolic Syndrome, Insulin Resistance, and Adiponectin Levels in Caucasian Patients with Obesity. Nutrients (2023).
2. Chronic Kidney Disease: Interaction of Adiponectin Gene Polymorphisms and Diabetes. International Journal of Molecular Sciences (2023).
3. Novel loci for triglyceride/HDL-C ratio longitudinal change among subjects without T2D. Journal of Lipid Research (2024).
4. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review. Archives of Endocrinology and Metabolism (2017).
5. Associations between polymorphisms of the ADIPOQ gene and hypertension risk: a systematic and meta-analysis. Scientific Reports (2017).